Evaluation of an Enzyme-Linked Immunosorbent Assay for the Diagnosis of Chagas' Disease using Synthetic Peptides

Vergara, U; Veloso, Cecilia; Gonzalez, Andrea; Lorca, Myriam

doi:10.4269/ajtmh.1992.46.39

Cited by 30 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By contrast, the serology of T. cruzi infected patients has been widely studied and antibody responses have been demonstrated using a variety of assays and antigens, positivity being accepted when serum samples have been tested in two or three conventional assays [11]. In the last few years, recombinant DNA technology has been used to address the present difficulty in preparing purified T. cruzi parasite antigens: isolated fusion proteins and synthetic peptides modelled according to the amino acid sequences have been used as antigens in an attempt to improve the diagnosis of chronic [12][13][14][15][16][17] and acute Chagas' disease [18,19].…”

Section: Introductionmentioning

confidence: 99%

Serological Diagnosis of Trypanosoma rangeli Infected Patients. A Comparison of Different Methods and its Implications for the Diagnosis of Chagas' Disease

Krusnell

A³

et al. 1997

Scand J Immunol

View full text Add to dashboard Cite

Vásquez JE, Krusnell J, Ö rn A, Sousa OE, Harris RA. Serological Diagnosis of Trypanosoma rangeli Infected Patients. A Comparison of Different Methods and its Implications for the Diagnosis of Chagas' Disease. Scand J Immunol 1997;45:322-330 Venous blood from 65 Panamanian schoolchildren living in an area endemic for both Trypanosoma cruzi and T. rangeli were screened for the presence of these parasites. Trypanosoma rangeli were isolated and cultured from four individuals. Serological tests of all 65 sera were performed, including immunohaemagglutination (IHA), indirect immunofluorescence assay (IF) and ELISA using both T. rangeli and T. cruzi as antigens, as well as T. cruzi synthetic peptides in an ELISA assay. Results indicated a higher immunoreactivity to T. rangeli preparations than to T. cruzi within the studied population, which could be divided into four 'serological responder' groups. Interestingly, the panel of SAPA and other T. cruzi synthetic peptides were not useful in the discrimination of patients. Furthermore, patients from whom parasites had been isolated could not be distinguished from those of two other groups. Significant immunoreactivity to T. cruzi preparations was displayed in all responder sera, despite total lack of evidence of infection with this parasite. The immunobiological significance of T. rangeli infection is unclear, but these data indicate that it is a compounding problem in the accurate diagnosis of pathological T. cruzi infection by serological analysis. The relationship of these cohabiting species, in respect to infection outcome and immunological activation, is discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

Serological Diagnosis of Trypanosoma rangeli Infected Patients. A Comparison of Different Methods and its Implications for the Diagnosis of Chagas' Disease

Krusnell

A³

et al. 1997

Scand J Immunol

View full text Add to dashboard Cite

show abstract

“…The rate of EIA SAPA reactivity in women chronically infected was consistent with other studies. 7,14,15 Among the 68 children in the study, 52.9% were girls and 60.3% were younger than 3 months of age. No children received transfusions.…”

mentioning

confidence: 99%

Early Diagnosis of Congenital Trypanosoma cruzi Infection, Using Shed Acute Phase Antigen, in Ushuaia, Tierra del Fuego, Argentina

Mallimaci¹,

Sosa-Estáni²,

Russomando³

et al. 2010

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Chagas' disease, or American trypanosomiasis, is caused by the protozoan parasite Trypanasoma cruzi . It is estimated that 15,000 new cases of congenital T. cruzi transmission occur in the Americas each year. The aim of this study was to estimate the rate of congenital T. cruzi infection in infants born to infected women living in Ushuaia, Argentina, as well to assess a serologic test using Shed Acute Phase Antigen (SAPA) for a timely diagnosis of congenital infection. The rate of congenital infection among children in the study was 4.4% (3/68). Our results show that for infants younger than 30 days of age, matched blood samples from mother and infant were capable of identifying congenital transmission of infection using an enzyme-linked immunosorbent assay with SAPA. For infants older than 3 months, congenital infection could be ruled out using the same procedure.Chagas' disease, or American trypanosomiasis, is caused by the protozoan parasite Trypanasoma cruzi . It is a major cause of morbidity and mortality in Latin America.

show abstract

“…In an attempt to improve the serological diagnosis of Chagas' disease and to avoid the problems of assay specificity and antigen obtainment, molecular techniques, such as gene cloning and expression, and the in vitro synthesis of the corresponding peptides allowed the identification and evaluation of a series of antigens that may be useful in diagnosis and vaccine development (10,14). Recent studies employing mixtures of synthetic peptides and/or recombinant antigens demonstrated an increase in assay sensitivity (11,14,16). …”

mentioning

confidence: 99%

Enzyme-Linked Immunosorbent Assay for Serological Diagnosis of Chagas' Disease Employing a Trypanosoma cruzi Recombinant Antigen That Consists of Four Different Peptides

et al. 2001

View full text Add to dashboard Cite

Serological tests to detect Trypanosoma cruzi antibodies have been used for screening blood donors, for epidemic studies, and for diagnosis of probably infected persons. Among different tests, the enzyme-linked immunosorbent assay (ELISA) with total, semipurified, or synthetic antigens has been widely used, mainly due to its easy automation. Aiming to improve serological studies concerning Chagas' disease, we have developed and evaluated a new test, the TcF-ELISA, using an artificially engineered recombinant antigen, which contains tandem sequences of different T. cruzi-specific peptides. The sensibility of the TcF-ELISA was determined with 101 serum samples from chagasic patients well-defined by clinical and epidemiological criteria. The specificity was determined with 39 serum samples from leishmaniasis or kala-azar patients and 150 serum samples from nonchagasic blood donors from Sao Paulo, Brazil. The TcF-ELISA showed 100% sensitivity and 98.94% of specificity. Compared with conventional ELISA (with semipurified T. cruzi epimastigote antigens), the TcF-ELISA showed advantages; for example, it distinguishes better between reagent and nonreagent serum and provides better precision and a lower occurrence of leishmaniasis cross-reactions. Our studies demonstrate high reproducibility between two different lots of the TcF ELISA and its applicability for the serological diagnosis of Chagas' disease.

show abstract

Evaluation of an Enzyme-Linked Immunosorbent Assay for the Diagnosis of Chagas' Disease using Synthetic Peptides

Cited by 30 publications

References 0 publications

Serological Diagnosis of Trypanosoma rangeli Infected Patients. A Comparison of Different Methods and its Implications for the Diagnosis of Chagas' Disease

Serological Diagnosis of Trypanosoma rangeli Infected Patients. A Comparison of Different Methods and its Implications for the Diagnosis of Chagas' Disease

Early Diagnosis of Congenital Trypanosoma cruzi Infection, Using Shed Acute Phase Antigen, in Ushuaia, Tierra del Fuego, Argentina

Enzyme-Linked Immunosorbent Assay for Serological Diagnosis of Chagas' Disease Employing a Trypanosoma cruzi Recombinant Antigen That Consists of Four Different Peptides

Contact Info

Product

Resources

About